FIELD: medicine; therapy.
SUBSTANCE: invention is intended for treatment and prevention of venous thrombosis after the novel coronavirus infection COVID-19. The method consists in four stages of the treatment, in which such drugs as Clexane, Vasoket, Voltaren, Actovegin, Thrombovazim, Xarelto or Eliquis, Thrombo ACC, Wessel Due F are used.
EFFECT: acceleration of the processes of recanalization of veins affected by the thrombotic process, reduction of the treatment time with no need for surgical intervention and laboratory control.
1 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR TREATMENT OF PATIENTS WITH ACUTE THROMBOPHLEBITIS OF SUPERFICIAL VEINS OF LOWER EXTREMITIES | 2021 |
|
RU2759653C1 |
METHOD OF TREATING PATIENTS WITH SEVERE FORMS OF REPERFUSION SYNDROME | 2023 |
|
RU2807877C1 |
METHOD OF TREATING PATIENTS WITH REPERFUSION SYNDROME | 2023 |
|
RU2807876C1 |
METHOD OF TREATING PATIENTS WITH POSTOPERATIVE LYMPHORRHEA | 2023 |
|
RU2807874C1 |
METHOD OF TREATING PATIENTS WITH SEVERE FORMS OF REPERFUSION SYNDROME COMPLICATED BY POSTOPERATIVE LYMPHORRHEA | 2023 |
|
RU2808921C1 |
METHOD OF COMPLEX TREATMENT OF PATIENTS WITH PURULONECROTIC COMPLICATIONS OF DIABETIC FOOT SYNDROME | 2020 |
|
RU2737491C1 |
METHOD OF TREATING ACUTE THROMBOSIS OF RETINA VEINS | 2010 |
|
RU2416402C1 |
METHOD OF TREATING SUBACUTE VENOUS THROMBOSIS OF VARIOUS LOCALISATIONS | 2015 |
|
RU2595238C1 |
ANTICOAGULANT DRUG, WHICH IS A SYNTHETIC DIPEPTIDE Ac-Trp-Arg-Pip·HCl, A PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTICOAGULANT DRUG | 2019 |
|
RU2712194C1 |
METHOD OF TREATING REPERFUSION SYNDROME IN PATIENTS WITH DIABETES MELLITUS FOLLOWING RE-VASCULARISATION OF LOWER EXTREMITY ARTERIES | 2014 |
|
RU2548739C1 |
Authors
Dates
2023-03-07—Published
2022-05-04—Filed